Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes

Transfusion

Volumn 57, Issue 9, 2017, Pages 2206-2215

  Worel, Nina ^a   Frank, Nelli ^b   Frech, Christian ^b   Fritsch, Gerhard ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CD34 ANTIGEN; CD38 ANTIGEN; CD45RA ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR; CD38 PROTEIN, HUMAN; CD45 ANTIGEN; HETEROCYCLIC COMPOUND; MEMBRANE PROTEIN; PROM1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CELL SUBPOPULATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MULTIPOTENT STEM CELL; ADOLESCENT; CELL DIFFERENTIATION; COMBINATION DRUG THERAPY; CYTOLOGY; DRUG EFFECTS; MIDDLE AGED; PROCEDURES; STANDARDS; STEM CELL MOBILIZATION; T LYMPHOCYTE SUBPOPULATION; YOUNG ADULT;

AC133 ANTIGEN; ADOLESCENT; ADULT; AGED; ANTIGENS, CD34; ANTIGENS, CD38; ANTIGENS, CD45; CELL DIFFERENTIATION; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; LYMPHOCYTE SUBSETS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; YOUNG ADULT;

EID: 85020198727     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14182     Document Type: Article

References (38)

1. Passweg JR, Baldomero H, Bader P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant 2016;51:786-92.
2. Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009;43:181-95.
3. Worel N, Rosskopf K, Neumeister P, et al. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Transfusion 2011;51:968-75.
4. Chabannon C, Bijou F, Miclea JM, et al. A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the “on-demand” scheme of administration at French autologous hematopoietic stem cell transplant programs. Transfusion 2015;55:2149-57.
5. D'Addio A, Curti A, Worel N, et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011;46:356-63.
6. Hübel K, Fresen MM, Salwender H, et al. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant 2011;46:1045-52.
7. Saraceni F, Shem-Tov N, Olivieri A, et al. Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective. Bone Marrow Transplant 2015;50:886-91.
8. Valtola J, Silvennoinen R, Ropponen A, et al. Blood graft cellular composition and early post-transplant recovery in myeloma patients mobilized with or without low-dose cyclophosphamide—a randomized comparison. Bone Marrow Transplant 2015;50:S18-S.
9. Varmavuo V, Mäntymaa P, Nousiainen T, et al. Blood graft composition after plerixafor injection in patients with NHL. Eur J Haematol 2012;89:128-35.
10. Varmavuo V, Mäntymaa P, Silvennoinen R, et al. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients. Transfusion 2013;53:1024-32.
11. Fruehauf S, Veldwijk MR, Seeger T, et al. A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study. Cytotherapy 2009;11:992-1001.
12. Roug AS, Hokland LB, Segel E, et al. Unraveling stem cell and progenitor subsets in autologous grafts according to methods of mobilization: implications for prediction of hematopoietic recovery. Cytotherapy 2014;16:392-401.
13. Varmavuo V, Rimpiläinen J, Kuitunen H, et al. Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients. Transfusion 2014;54:1243-50.
14. Taubert I, Saffrich R, Zepeda-Moreno A, et al. Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor. Cytotherapy 2011;13:459-66.
15. Görgens A, Radtke S, Horn PA, et al. New relationships of human hematopoietic lineages facilitate detection of multipotent hematopoietic stem and progenitor cells. Cell Cycle 2013;12:3478-82.
16. Görgens A, Radtke S, Möllmann M, et al. Revision of the human hematopoietic tree: granulocyte subtypes derive from distinct hematopoietic lineages. Cell Rep 2013;3:1539-52.
17. Dmytrus J, Matthes-Martin S, Pichler H, et al. Multi-color immune-phenotyping of CD34 subsets reveals unexpected differences between various stem cell sources. Bone Marrow Transplant 2016;51:1093-100.
18. Görgens A, Ludwig AK, Möllmann M, et al. Multipotent hematopoietic progenitors divide asymmetrically to create progenitors of the lymphomyeloid and erythromyeloid lineages. Stem Cell Reports 2014;3:1058-72.
19. Keeney M, Chin-Yee I, Weir K, et al. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. Cytometry 1998;34:61-70.
20. Fritsch G, Frank N, Dmytrus J, et al. Relevance of flow cytometric enumeration of post-thaw leucocytes: influence of temperature during cell staining on viable cell recovery. Vox Sang 2016;111:187-96.
21. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4767-73.
22. DiPersio JF, Stadtmauer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009;113:5720-6.
23. Worel N, Fritsch G, Agis H, et al. Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure. J Clin Apher 2017;32:224-34.
24. Cheng J, Schmitt M, Wuchter P, et al. Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma. Transfusion 2015;55:275-83.
25. Lanza F, Gardellini A, Laszlo D, et al. Plerixafor: what we still have to learn. Expert Opin Biol Ther 2015;15:143-7.
26. Terstappen LW, Huang S, Safford M, et al. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells. Blood 1991;77:1218-27.
27. Adolfsson J, Månsson R, Buza-Vidas N, et al. Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential: a revised road map for adult blood lineage commitment. Cell 2005;121:295-306.
28. Donahue RE, Jin P, Bonifacino AC, et al. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures. Blood 2009;114:2530-41.
29. Schroeder MA, Rettig MP, Lopez S, et al. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. Blood 2017;129:2680-92.
30. Valtola J, Varmavuo V, Ropponen A, et al. Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison. Transfusion 2015;55:2358-68.
31. Jiang L, Malik S, Litzow M, et al. Hematopoietic stem cells from poor and good mobilizers are qualitatively equivalent. Transfusion 2012;52:542-8.
32. Bernardini G, Sciumè G, Bosisio D, et al. CCL3 and CXCL12 regulate trafficking of mouse bone marrow NK cell subsets. Blood 2008;111:3626-34.
33. Gaugler B, Arbez J, Legouill S, et al. Characterization of peripheral blood stem cell grafts mobilized by granulocyte colony-stimulating factor and plerixafor compared with granulocyte colony-stimulating factor alone. Cytotherapy 2013;15:861-8.
34. Porrata LF, Gertz MA, Geyer SM, et al. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2004;18:1085-92.
35. Porrata LF, Inwards DJ, Micallef IN, et al. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol 2002;117:629-33.
36. Porrata LF, Litzow MR, Inwards DJ, et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 2004;33:291-8.
37. Hiwase DK, Hiwase S, Bailey M, et al. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2008;14:116-24.
38. Porrata LF, Gastineau DA, Padley D, et al. Re-infused autologous graft natural killer cells correlates with absolute lymphocyte count recovery after autologous stem cell transplantation. Leuk Lymphoma 2003;44:997-1000.